Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 4/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 2/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836436 | 0.83 | CYP11B2 (0.40) | CYP11B2CFTRMAPK8MAPK10SMO | |
| SCHEMBL17441159 | 0.83 | IRAK4 (0.49) | CFTRKHKKMOIRAK4 | |
| SCHEMBL16300044 | 0.80 | SMO (0.55) | CYP11B2SMONR3C1PGR | |
| SCHEMBL30186312 | 0.80 | NR3C1 (0.51) | CYP11B2CYP11B1LRRK2MAPK8MAPK10 | |
| SCHEMBL16634158 | 0.80 | NR3C1 (0.51) | CYP11B2CYP11B1LRRK2MAPK8MAPK10 | |
| SCHEMBL2627244 | 0.76 | IRAK4 (0.53) | CYP11B2CYP11B1LRRK2MAPK8MAPK10 | |
| SCHEMBL18289116 | 0.76 | CYP11B2 (0.47) | CYP11B2CYP11B1LRRK2MAPK8MAPK10 | |
| SCHEMBL30032844 | 0.76 | HPGD (0.54) | CYP11B2CYP11B1LRRK2MGAMGAA | |
| SCHEMBL2548808 | 0.76 | KHK (0.56) | CYP11B2CYP11B1LRRK2MAPK8MAPK10 | |
| SCHEMBL30918020 | 0.76 | CYP11B2 (0.54) | CYP11B2CYP11B1LRRK2MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2012054332-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054332-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | CYP11B2 1943/4885CYP11B1 1502/4885CFTR 2036/4885 |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | CYP11B2 1943/4885CYP11B1 1502/4885CFTR 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.